Winner Profile
Zhiwen Zhou
CEO, Staidson Beijing Biopharmaceuticals
Industry: Biotechnology
Company size: X-Small
Published: 2016-10-17
Is Staidson Beijing Biopharmaceuticals a good stock investment?
Based on the annual Obermatt CEO of the Year analysis, Zhiwen Zhou (Staidson Beijing Biopharmaceuticals) earned the following Obermatt pins for the management performance.
Obermatt accolades Zhiwen Zhou
| Year | Pin | Category |
|---|---|---|
| 2016 |  |
Investment Performance |
|
Combined Performance | |
|
Operating Performance | |
|
Growth Performance | |
| 2015 |  |
Operating Performance |
|
Growth Performance | |
|
Combined Performance | |
| 2014 |  |
Growth Performance |
Zhiwen Zhou was included in the competition among China Top 100 Growth Companies (China) (current winners). See the winners of the other competitions or how the CEOs performed over all competitions.
Performance Overview Zhiwen Zhou
In summary, Zhiwen Zhou obtained the following achievements in the individual Obermatt categories by participating in the Obermatt rankings (averages of all evaluated rankings are shown for this CEO, also for other companies):
CEO performance is displayed relative to that of other CEOs that competed in the same categories for the same number of competitions. A ranking of 70 in Combined Performance indicates that Zhiwen Zhou was better than 70% of all other CEOs that were analyzed as part of the China Top 100 Growth Companies – China for three participations in Obermatt CEO competitions. Zhiwen Zhou’s average ranking can be found in the Multi-Year Rankings for China Top 100 Growth Companies - China.